<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cumberland Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/cumberland-pharmaceuticals-inc</link>
<description>Latest news and press releases for Cumberland Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cumberland-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683558a878dffbe2df0eab30.webp</url>
<title>Cumberland Pharmaceuticals Inc</title>
<link>https://6ix.com/company/cumberland-pharmaceuticals-inc</link>
</image>
<item>
<title>Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex</title>
<link>https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-announces-strategic-transaction-to-integrate-commercial-business-with-apotex</link>
<guid isPermaLink="true">https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-announces-strategic-transaction-to-integrate-commercial-business-with-apotex</guid>
<pubDate>Thu, 23 Apr 2026 13:00:00 GMT</pubDate>
<description>Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a U.S. specialty pharmaceutical company, today announced it has entered into an agreement with an affiliate of Apotex ("Apotex"), the largest Canadian based pharmaceutical company to integrate their branded U.S. businesses. Under the terms of the agreement, Apotex will acquire Cumberland's line of branded pharmaceuticals for cash consideration of $100 million, and create a platform to deliver specialty medicines that improve the quality of patient</description>
</item>
<item>
<title>CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE</title>
<link>https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-announces-expanded-indication-for-caldolorr-ibuprofen-injection-and-launch-of-new-brand-website</link>
<guid isPermaLink="true">https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-announces-expanded-indication-for-caldolorr-ibuprofen-injection-and-launch-of-new-brand-website</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>A Safe and Effective Non-Opioid Pain Management SolutionNASHVILLE, Tenn., April 16, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a</description>
</item>
<item>
<title>Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting</title>
<link>https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-launches-new-sancusor-website-featuring-educational-resources-for-chemotherapy-induced-nausea-and-vomiting</link>
<guid isPermaLink="true">https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-launches-new-sancusor-website-featuring-educational-resources-for-chemotherapy-induced-nausea-and-vomiting</guid>
<pubDate>Tue, 17 Mar 2026 13:05:00 GMT</pubDate>
<description>Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company today announced the launch of its new Sancuso® (granisetron transdermal system) website. The website is designed to provide health care professionals and patients with enhanced access to educational resources, clinical information and expert insights related to the prevention of chemotherapy-induced nausea and vomiting (CINV). The website also features the brand's key message: "Sancuso – the Difference between Lif</description>
</item>
<item>
<title>CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH</title>
<link>https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-reports-31percent-fourth-quarter-2025-revenue-growth-28</link>
<guid isPermaLink="true">https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-reports-31percent-fourth-quarter-2025-revenue-growth-28</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>Cumberland to highlight 2025 financial, international, portfolio and clinical progressNASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cumberland</description>
</item>
<item>
<title>CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®</title>
<link>https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-launches-us-promotion-of-taliciar</link>
<guid isPermaLink="true">https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-launches-us-promotion-of-taliciar</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>NASHVILLE, Tenn., Feb. 25, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new</description>
</item>
<item>
<title>CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE</title>
<link>https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-to-announce-2025-annual-financial-results-and-company-update</link>
<guid isPermaLink="true">https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-to-announce-2025-annual-financial-results-and-company-update</guid>
<pubDate>Tue, 24 Feb 2026 21:05:00 GMT</pubDate>
<description>Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its 2025 financial results and provide a company update after the market closes on Tuesday, March 3, 2026.</description>
</item>
<item>
<title>Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program</title>
<link>https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-receives-fda-fast-140500561</link>
<guid isPermaLink="true">https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-receives-fda-fast-140500561</guid>
<pubDate>Wed, 04 Feb 2026 14:05:00 GMT</pubDate>
<description>Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its novel oral therapy targeting a fatal form of heart disease in Duchenne muscular dystrophy (DMD) patients.</description>
</item>
<item>
<title>CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT</title>
<link>https://6ix.com/company/cumberland-pharmaceuticals-inc/news/caldolor-ibuprofen-injection-cms-issued-140500938</link>
<guid isPermaLink="true">https://6ix.com/company/cumberland-pharmaceuticals-inc/news/caldolor-ibuprofen-injection-cms-issued-140500938</guid>
<pubDate>Mon, 08 Dec 2025 14:05:00 GMT</pubDate>
<description>Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), today announced an important update regarding its Caldolor® (ibuprofen) Injection. The product's permanent J-code, J1741, is now officially associated with a reimbursement price, providing healthcare providers with a CMS-covered, non-opioid option for managing pain and fever.</description>
</item>
<item>
<title>RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement</title>
<link>https://6ix.com/company/cumberland-pharmaceuticals-inc/news/redhill-biopharma-successfully-regains-compliance-with-nasdaq-stockholders-equity-requirement</link>
<guid isPermaLink="true">https://6ix.com/company/cumberland-pharmaceuticals-inc/news/redhill-biopharma-successfully-regains-compliance-with-nasdaq-stockholders-equity-requirement</guid>
<pubDate>Mon, 01 Dec 2025 12:00:00 GMT</pubDate>
<description>RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that on November 26, 2025, it received confirmation from the Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1)1.</description>
</item>
<item>
<title>CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH</title>
<link>https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-reports-12-date-220000042</link>
<guid isPermaLink="true">https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-reports-12-date-220000042</guid>
<pubDate>Tue, 04 Nov 2025 22:00:00 GMT</pubDate>
<description>Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $8.3 million during the third quarter of 2025. Year-to-date revenues for the first nine months of the year totaled $30.8 million, representing an increase of 12% over the first nine months of 2024.</description>
</item>
<item>
<title>CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE</title>
<link>https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-announce-q3-2025-200500080</link>
<guid isPermaLink="true">https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-announce-q3-2025-200500080</guid>
<pubDate>Tue, 28 Oct 2025 20:05:00 GMT</pubDate>
<description>Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2025 financial results and provide a Company update after the market closes on Tuesday, Nov. 4, 2025.</description>
</item>
<item>
<title>RedHill Biopharma Receives Nasdaq Staff Determination Notification</title>
<link>https://6ix.com/company/cumberland-pharmaceuticals-inc/news/redhill-biopharma-receives-nasdaq-staff-determination-notification</link>
<guid isPermaLink="true">https://6ix.com/company/cumberland-pharmaceuticals-inc/news/redhill-biopharma-receives-nasdaq-staff-determination-notification</guid>
<pubDate>Wed, 22 Oct 2025 20:50:00 GMT</pubDate>
<description>RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that on October 16, 2025, it received a Nasdaq Staff Determination letter indicating that the Company had not met the minimum stockholders' equity requirements ("Minimum Equity Requirement") for continued listing, pursuant to Listing Rule 5550(b)(1), by the required compliance date of October 13, 2025.</description>
</item>
<item>
<title>CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO</title>
<link>https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-phamaceuticals-announces-addition-established-130500411</link>
<guid isPermaLink="true">https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-phamaceuticals-announces-addition-established-130500411</guid>
<pubDate>Mon, 20 Oct 2025 13:05:00 GMT</pubDate>
<description>Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced strategic arrangements with RedHill Biopharma Ltd. (Nasdaq: RDHL), a specialty biopharmaceutical company, to jointly commercialize Talicia®. The FDA-approved oral capsule is indicated for the treatment of Helicobacter pylori infection in adults, a bacterial infection and leading risk factor for gastric cancer.</description>
</item>
<item>
<title>CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.</title>
<link>https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-vibativ-added-national-130500650</link>
<guid isPermaLink="true">https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-vibativ-added-national-130500650</guid>
<pubDate>Mon, 13 Oct 2025 13:05:00 GMT</pubDate>
<description>Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, has added their potent antibiotic, Vibativ® (telavancin), to a national group purchasing agreement with Premier, Inc. Effective October 1, 2025 the product addition allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Vibativ® in both the 12-vial carton and the newly introduced 4-vial Starter Pak.</description>
</item>
<item>
<title>CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO</title>
<link>https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-announces-product-approval-130500097</link>
<guid isPermaLink="true">https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-announces-product-approval-130500097</guid>
<pubDate>Wed, 01 Oct 2025 13:05:00 GMT</pubDate>
<description>Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that its ibuprofen injection product, has received regulatory approval in Mexico.</description>
</item>
<item>
<title>TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA</title>
<link>https://6ix.com/company/cumberland-pharmaceuticals-inc/news/tabuk-launches-vibativ-fda-approved-130500725</link>
<guid isPermaLink="true">https://6ix.com/company/cumberland-pharmaceuticals-inc/news/tabuk-launches-vibativ-fda-approved-130500725</guid>
<pubDate>Mon, 29 Sep 2025 13:05:00 GMT</pubDate>
<description>Specialty pharmaceutical companies Tabuk Pharmaceutical Manufacturing Company a fully owned subsidiary of Astra Industrial Group and a leading pharmaceutical company in the Middle East and Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced the launch of Cumberland's Vibativ® (telavancin) injection in Saudi Arabia.</description>
</item>
<item>
<title>Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date</title>
<link>https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-reports-23-revenue-200500472</link>
<guid isPermaLink="true">https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-reports-23-revenue-200500472</guid>
<pubDate>Tue, 05 Aug 2025 20:05:00 GMT</pubDate>
<description>Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $10.8 million during the second quarter of 2025, a 10% increase over the prior year period. Year-to-date revenues for the first six months of the year totaled $22.6 million, representing an increase of 23% over the first half of 2024.</description>
</item>
<item>
<title>CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK</title>
<link>https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-receives-vizient-contract-130500565</link>
<guid isPermaLink="true">https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-receives-vizient-contract-130500565</guid>
<pubDate>Mon, 04 Aug 2025 13:05:00 GMT</pubDate>
<description>Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced the availability of the Vibativ® (telavancin) 4-Vial Starter Pak through a new contract with Vizient®, the nation's largest provider-driven healthcare performance improvement company.</description>
</item>
<item>
<title>CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE</title>
<link>https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-announce-q2-2025-200500780</link>
<guid isPermaLink="true">https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-announce-q2-2025-200500780</guid>
<pubDate>Tue, 29 Jul 2025 20:05:00 GMT</pubDate>
<description>Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2025 financial results and provide a Company update after the market closes on Tuesday, August 5, 2025.</description>
</item>
<item>
<title>Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference</title>
<link>https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-shares-phase-2-130500600</link>
<guid isPermaLink="true">https://6ix.com/company/cumberland-pharmaceuticals-inc/news/cumberland-pharmaceuticals-shares-phase-2-130500600</guid>
<pubDate>Mon, 23 Jun 2025 13:05:00 GMT</pubDate>
<description>Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company committed to developing new products for rare diseases, shared the latest positive results from its Phase 2 FIGHT DMD trial evaluating ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease, at the annual Parent Project Muscular Dystrophy (PPMD) conference in Las Vegas. These new results highlight multiple indicators of cardiac benefit with ifetroban treatment in DMD heart disease, the</description>
</item>
</channel>
</rss>